ATE247949T1 - Arzneistoffverabreichungssystem mit zweistufigem targeting - Google Patents

Arzneistoffverabreichungssystem mit zweistufigem targeting

Info

Publication number
ATE247949T1
ATE247949T1 AT98962780T AT98962780T ATE247949T1 AT E247949 T1 ATE247949 T1 AT E247949T1 AT 98962780 T AT98962780 T AT 98962780T AT 98962780 T AT98962780 T AT 98962780T AT E247949 T1 ATE247949 T1 AT E247949T1
Authority
AT
Austria
Prior art keywords
drug
delivery system
drug delivery
target
cells
Prior art date
Application number
AT98962780T
Other languages
English (en)
Inventor
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Original Assignee
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katarina Edwards, Joergen Carlsson, Stefan Sjoeberg filed Critical Katarina Edwards
Application granted granted Critical
Publication of ATE247949T1 publication Critical patent/ATE247949T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98962780T 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting ATE247949T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
PCT/SE1998/002231 WO1999029302A1 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting

Publications (1)

Publication Number Publication Date
ATE247949T1 true ATE247949T1 (de) 2003-09-15

Family

ID=20409286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962780T ATE247949T1 (de) 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting

Country Status (10)

Country Link
US (1) US6562316B1 (de)
EP (1) EP1033972B1 (de)
JP (1) JP2001525356A (de)
AT (1) ATE247949T1 (de)
AU (1) AU745059B2 (de)
CA (1) CA2312767C (de)
DE (1) DE69817602T2 (de)
DK (1) DK1033972T3 (de)
SE (1) SE513149C2 (de)
WO (1) WO1999029302A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
EP0963758A3 (de) * 1998-05-07 2000-03-22 Universiteit Gent Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
ATE340592T1 (de) 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2427146A1 (en) 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1877099B1 (de) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutische konjugate beinhaltend ein lysosomales enzym, polysialinsäure und eine zielkomponente
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
US8808733B2 (en) 2009-03-31 2014-08-19 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
WO2012112317A1 (en) * 2011-02-15 2012-08-23 Albert Einstein College Of Medicine Of Yeshiva University Radiobacteria for therapy of cancer
ES2992024T3 (es) 2011-06-23 2024-12-05 Dsm Ip Assets Bv Nuevos copolímeros de poliesteramida biodegradables para la administración de fármacos
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
EP3368687B1 (de) * 2015-10-27 2021-09-29 The Broad Institute, Inc. Zusammensetzungen und verfahren gegen krebsspezifische sequenzvariationen
WO2021019575A1 (en) 2019-08-01 2021-02-04 Indian Institute Of Science A method for locomotion of a nanorobot and implementations thereof
CA3160955A1 (en) 2019-11-12 2021-05-20 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613937B1 (fr) * 1987-04-17 1989-07-21 Ire Celltarg Sa Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
US5328678A (en) * 1987-11-04 1994-07-12 Vestar, Inc. Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
EP0626943B1 (de) * 1991-10-31 2000-01-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Bistriazene als chemotherapeutische wirkstoffe
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
EP0723664A1 (de) * 1993-10-15 1996-07-31 Eva M. Rakowicz-Szulczynska Nachweiss und behandlung brustkrebsund gynäkologischer krebs
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US6180766B1 (en) * 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ，インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
US5630786A (en) * 1994-06-27 1997-05-20 Ionix Corporation Boron neutron capture enhancement of fast neutron therapy
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CZ299809B6 (cs) * 1996-05-08 2008-12-03 Nika Health Products Limited Lipidový vácek mající kladne nabitou membránu z lipidové dvojvrstvy pro prenos genetického materiálu a zpusob jeho prípravy
DE69727384T2 (de) * 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion

Also Published As

Publication number Publication date
CA2312767A1 (en) 1999-06-17
WO1999029302A1 (en) 1999-06-17
US6562316B1 (en) 2003-05-13
JP2001525356A (ja) 2001-12-11
SE9704549L (sv) 1999-06-06
AU1793899A (en) 1999-06-28
SE513149C2 (sv) 2000-07-17
EP1033972B1 (de) 2003-08-27
SE9704549D0 (sv) 1997-12-05
DE69817602T2 (de) 2004-06-24
CA2312767C (en) 2009-04-07
DK1033972T3 (da) 2003-12-22
EP1033972A1 (de) 2000-09-13
AU745059B2 (en) 2002-03-07
DE69817602D1 (de) 2003-10-02

Similar Documents

Publication Publication Date Title
ATE247949T1 (de) Arzneistoffverabreichungssystem mit zweistufigem targeting
NZ336511A (en) Treating prostatic diseases using delayed and/or sustained release formulations of activated vitamin D
MY116474A (en) Potentiation of temozolomide in human tumour cells
EP1455840A4 (de) Behandlung von krebs bei menschen mit adenovirus-vektor tnf-alpha
AU3354500A (en) Dramatic simplification of a method to treat neoplastic disease by radiation
AU4338501A (en) Combination chemotherapy
AU2001236529A1 (en) Combination therapy for cancer
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
Dische Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma
Looney et al. Solid tumor models for the assessment of different treatment modalities. XXII. The alternate utilization of radiotherapy and chemotherapy
RU94035764A (ru) Способ лечения онкологического заболевания
Clark et al. Biologic treatment of human cancer
Hopkins et al. The effect of varying the time between irradiation and cyclophosphamide on growth response of hepatoma 3924A
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
Hopkins et al. Synchronization of host and tumor responses for sequential therapy in experimental solid tumors
UA30257A (uk) Спосіб нормалізації тканинного обміну та відновлення морфофункціонального стану органів і тканин
RU94021014A (ru) Способ лечения злокачественных опухолей методом фотодинамической терапии
Dörr 100The three A's of normal tissue repopulation: cceleration, symmetry loss, and bortive divisions
IL153586A0 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
Meral et al. Role of vitamin E in decreasing the toxic effect of digoxin
Struwig Microcurrent therapy
UA20727A (uk) Спосіб лікуваhhя раку легеhі шляхом хіміоімуhотерапії
Turrisi Don’t be mis-guided when the data are silent and the editorial misses the mark.
Brahme 103Inverse therapy planning and treatment optimization
Thames 102Altered fractionation: The past and the future

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties